These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32593400)

  • 41. Cancer stem cell, niche and EGFR decide tumor development and treatment response: A bio-computational simulation study.
    Zhu X; Zhou X; Lewis MT; Xia L; Wong S
    J Theor Biol; 2011 Jan; 269(1):138-49. PubMed ID: 20969880
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
    Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
    J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors.
    Cruz-López O; Conejo-García A; Núñez MC; Kimatrai M; García-Rubiño ME; Morales F; Gómez-Pérez V; Campos JM
    Curr Med Chem; 2011; 18(7):943-63. PubMed ID: 21254978
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.
    Pines G; Köstler WJ; Yarden Y
    FEBS Lett; 2010 Jun; 584(12):2699-706. PubMed ID: 20388509
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
    Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
    Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting ErbB receptors in high-grade glioma.
    Berezowska S; Schlegel J
    Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
    Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer.
    Codony-Servat J; Codony-Servat C; Cardona AF; Giménez-Capitán A; Drozdowskyj A; Berenguer J; Bracht JWP; Ito M; Karachaliou N; Rosell R
    Clin Lung Cancer; 2019 May; 20(3):167-177. PubMed ID: 30885551
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
    Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
    Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy.
    Steelman LS; Fitzgerald T; Lertpiriyapong K; Cocco L; Follo MY; Martelli AM; Neri LM; Marmiroli S; Libra M; Candido S; Nicoletti F; Scalisi A; Fenga C; Drobot L; Rakus D; Gizak A; Laidler P; Dulinska-Litewka J; Basecke J; Mijatovic S; Maksimovic-Ivanic D; Montalto G; Cervello M; Milella M; Tafuri A; Demidenko Z; Abrams SL; McCubrey JA
    Curr Pharm Des; 2016; 22(16):2358-88. PubMed ID: 26947958
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics.
    Mitchell RA; Luwor RB; Burgess AW
    Exp Cell Res; 2018 Oct; 371(1):1-19. PubMed ID: 30098332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer.
    Tsai YC; Zeng T; Abou-Kheir W; Yeh HL; Yin JJ; Lee YC; Chen WY; Liu YN
    Mol Cancer; 2018 Feb; 17(1):42. PubMed ID: 29455655
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency.
    Hu S; Fu W; Li T; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Shen Y; Lin F; Tang Y; Ye X; Yang Y; Lei C
    Sci Transl Med; 2017 Mar; 9(380):. PubMed ID: 28275151
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
    Eng J; Woo KM; Sima CS; Plodkowski A; Hellmann MD; Chaft JE; Kris MG; Arcila ME; Ladanyi M; Drilon A
    J Thorac Oncol; 2015 Dec; 10(12):1713-9. PubMed ID: 26334752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting.
    Saito R; Miki Y; Ishida N; Inoue C; Kobayashi M; Hata S; Yamada-Okabe H; Okada Y; Sasano H
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.